ProBio's AAV Manufacturing Excellence Powers UC Irvine and GlyTR Therapeutics First‑in‑Class pan-cancer CAR‑T Program
HOPEWELL, N.J., Jul 1, 2026 /PRNewswire/ -- The University of California, Irvine (UC Irvine) School of Medicine and GlyTR Therapeutics have developed a next‑generation AAV‑mediated CAR T‑cell platform, GlyTR (pronounced 'glitter'), engineered to target tumor‑associated carbohydrate...
HOPEWELL, N.J., Jul 1, 2026 /PRNewswire/ -- The University of California, Irvine (UC Irvine) School of Medicine and GlyTR Therapeutics have developed a next‑generation AAV‑mediated CAR T‑cell platform, GlyTR (pronounced 'glitter'), engineered to target tumor‑associated carbohydrate...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.